-
2 weeks ago | 
caixinglobal.com | Cui Xiaotian |Lu Zhenhua
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
The U.S. Food and Drug Administration on Friday approved the first blood test to aid in the diagnosis of Alzheimer's disease, a move that could simplify and expedite the detection of the neurodegenerative condition. The test, named Lumipulse G, is intended for patients aged 55 and older who are exhibiting symptoms consistent with Alzheimer's.
-
1 month ago | 
caixinglobal.com | Cui Xiaotian |Denise Jia
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
British-Swedish pharmaceutical giant AstraZeneca plc is facing increasing scrutiny in China, with authorities accusing the company of evading more than $1.6 million in import taxes as part of a widening smuggling investigation that now includes a top-selling breast cancer drug.
-
1 month ago | 
caixinglobal.com | Cui Xiaotian |Kelly Wang
Explore the story in 3 minutesChina's medical equipment industry is under pressure due to the intensifying trade tensions between the United States and China, largely caused by high tariffs. The U.S., which imposed tariffs of up to 245% on some Chinese imports, is China’s second-largest trade partner in medical and pharmaceutical products after the European Union. In 2024, trade between the two nations reached $34.1 billion [para. 1][para. 2].
-
1 month ago | 
caixinglobal.com | Cui Xiaotian |Kelly Wang
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
China’s medical equipment sector is beginning to feel the strain from the escalating trade tensions between the world’s two largest economies.
-
Mar 4, 2025 | 
caixinglobal.com | Cui Xiaotian |Denise Jia
China has banned Illumina, the U.S. genomics giant, from exporting gene sequencing machines to the country, escalating sanctions imposed last month when the company was added to Beijing’s Unreliable Entity List.
The move is expected to accelerate domestic alternatives in the gene sequencing industry.
Illumina, a dominant player in the global gene sequencing industry, has been a major supplier in China since entering the market in 2005.
-
Mar 4, 2025 | 
caixinglobal.com | Cui Xiaotian |Denise Jia
China has banned Illumina, the U.S. genomics giant, from exporting gene sequencing machines to the country, escalating sanctions imposed last month when the company was added to Beijing’s Unreliable Entity List. The move is expected to accelerate domestic alternatives in the gene sequencing industry. Illumina, a dominant player in the global gene sequencing industry, has been a major supplier in China since entering the market in 2005.
-
Feb 12, 2025 | 
caixinglobal.com | Cui Xiaotian |Kelly Wang
00:00/00:00 您的浏览器不支持 audio 标签。 Listen to this article 1x New data discrepancies involving generic drug approvals in China have added to concerns that led a national regulator to suspend public access to the information for more than two weeks earlier this year to correct the problems. Statistical errors persist in the restored Center for Drug Evaluation (CDE) data, and problems with the drug approval data submission process have surfaced as an issue, Caixin has learned.
-
Feb 12, 2025 | 
caixinglobal.com | Cui Xiaotian |Kelly Wang
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
New data discrepancies involving generic drug approvals in China have added to concerns that led a national regulator to suspend public access to the information for more than two weeks earlier this year to correct the problems.
-
Feb 5, 2025 | 
caixinglobal.com | Zhou Xinda |Cui Xiaotian |Jiang Moting |Kelly Wang
Personalised advertising and content, advertising and content measurement, audience research and services developmentStore and/or access information on a deviceYou can choose how your personal data is used.
-
Feb 5, 2025 | 
caixinglobal.com | Zhou Xinda |Cui Xiaotian |Jiang Moting |Kelly Wang
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
In a bid to lower the prices the Chinese state and public pay for medicines, Beijing implemented its centralized procurement policy in 2018. Under this system, the drugs are included by China’s state-run health care insurance and negotiated on a national basis.
Ever since, it’s been fiercely debated whether or not the hard bargains driven by the government undermine drugs’ quality.
